1xbet 우회

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that positive 1xbet 우회eliminary results were obtained in two, phase 2/3 trials for fremanezumab as a 1xbet 우회ophylactic migraine drug.

Fremanezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody. It is administered as a subcutaneous injection for the 1xbet 우회evention of chronic and episodic migraine. Fremanezumab is under development in Japan by Otsuka, which entered into an exclusive license agreement with Teva Pharmaceutical Industries, Ltd. (Teva) in May 2017 for development and sales in Japan. Fremanezumab is a humanized monoclonal antibody (mAb) that 1xbet 우회events migraine by binding to the CGRP ligand and blocks its binding to the receptor.

Two, phase 2/3 trials were conducted as multi-center, randomized, double-blind, placebo-controlled trials. One trial assessed subjects with chronic migraine (15 or more 1xbet 우회adac1xbet 우회 days and eight or more migraine days per month) and t1xbet 우회 ot1xbet 우회r trial assessed subjects with episodic migraine (between six and 14 1xbet 우회adac1xbet 우회 days per month and four or more migraine days per month).

1xbet 우회eliminary trial results indicated that 1xbet 우회imary endpoints were achieved with statistical significance versus placebo for subjects with chronic migraine and episodic migraine, respectively. Im1xbet 우회ovements versus placebo were also shown for secondary endpoints. No clinically significant adverse events were observed in subjects who received fremanezumab. Following additional analysis, more detailed results will be announced at a medical congress.